SGAM
KRTX

Smith Group Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Smith Group Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20
Closed -$3K – 370
2021
Q4 		$3K Hold
20
– – ﹤0.01% 358
2021
Q3 		$2K Buy
+20
New +$2.31K ﹤0.01% 366

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Smith Group Asset Management's KRTX Position: Q1 2022 in Review

Smith Group Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022, closing a stake of 20 shares — an estimated $3K sold.

Smith Group Asset Management first reported a position in KRTX in Q3 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

  • Smith Group Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Smith Group Asset Management sold 20 Karuna Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $3K.
  • Smith Group Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Smith Group Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $3K in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Smith Group Asset Management's 13F filing for Q1 2022, filed 5 May 2022.